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Abstract
Background: Scientific and professional development opportunities for early career scientists in low- and middle-
income countries (LMICs) are limited and not consistent. There is a disproportionately low number of biomedical
and clinical researchers in LMIC’s relative to their high burden of disease, a disparity that is aggravated by emigration of
up to 70% of scientists from their countries of birth for education and employment elsewhere. To help address this
need, a novel University-accredited, immersive fellowship program was established by a large public-academic-private
network. We sought to describe the program and summarize progress and lessons learned over its first 7-years.
Methods: Hallmarks of the program are a structured learning curriculum and bespoke research activities tailored to the
needs of each fellow. Research projects expose the scientists to state-of-the-art methodologies and leading experts in
their fields while also ensuring that learnings are implementable within their home infrastructure. Fellows run seminars
on drug discovery and development that reinforce themes of scientific leadership and teamwork together with practical
modules on addressing healthcare challenges within their local systems. Industry mentors achieve mutual learning to
better understand healthcare needs in traditionally underserved settings. We evaluated the impact of the program
through an online survey of participants and by assessing research output.
Results: More than 140 scientists and clinicians from 25 countries participated over the 7-year period. Evaluation
revealed strong evidence of knowledge and skills transfer, and beneficial self-reported impact on fellow’s research output
and career trajectories. Examples of program impact included completion of post-graduate qualifications; establishment
and implementation of good laboratory- and clinical- practice mechanisms; and becoming lead investigators in local
programs. There was a high retention of fellows in their home countries (> 75%) and an enduring professional network
among the fellows and their mentors.
Conclusions: Our experience demonstrates an example for how multi-sectoral partners can contribute to scientific and
professional development of researchers in LMICs and supports the idea that capacity-building efforts should be tailored
to the specific needs of beneficiaries to be maximally effective. Lessons learned may be applied to the design and
conduct of other programs to strengthen science ecosystems in LMICs.
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Background
Establishing sustainable research in science ecosystems in
low- and middle-income countries (LMICs) is an urgent
priority but no small task [1–3]. In these countries, the
number of biomedical and clinical researchers is dispro-
portionately low relative to the high burden of disease, a
disparity that is aggravated by emigration of up to 70% of
scientists from their countries of birth in pursuit of educa-
tion and employment elsewhere [4–6]. To break this
self-propagating cycle, scientific research infrastructures
in LMICs will need to develop to a tipping point beyond
which scientists have greater professional incentives to re-
main in their home countries. There have been major ef-
forts to strengthen science systems in LMICs, including
collaborations focused on capacity-building involving local
research institutions and global stakeholders. These pro-
grams have met with various levels of success [7–11].
However, much more progress is needed.
Achievements in science and medicine that impact hu-
manity in LMICs ultimately depend on communities of
scientists and clinicians that live and work in those re-
gions. Human capital development is an important com-
ponent to improvement of science and medical capacity in
LMICs [2, 3]. Local scientific training curricula that are
contemporary and high-quality have expanded over the
past decade [12, 13]. To maintain this momentum, com-
prehensive knowledge and skills training must continue
and be expanded across a range of scientific disciplines.
In response to needs for enhanced professional develop-
ment for scientists in LMICs, a novel fellowship training
program has been implemented over the past 7 years by a
network of public, academic and private partners. Target
beneficiaries were Master’s, PhD, and post-doctoral scientists
and clinicians who wished to pursue scientific and leadership
skills development to complement instruction at their home
institution. The program’s central theme was individualized
mentoring, and research activities were tailored to the
unique needs of each participant. The core program took
place annually over a 3-month period in Switzerland, where
fellows received on-site tutoring at Novartis’ research and
development laboratories followed by accreditation from the
University of Basel. Mentoring and collaboration often con-
tinued long after completion of the core program. The ini-
tiative was named the “Next Generation Scientist” (NGS)
program to highlight its stated objective of contributing to
the development of future scientific leaders in LMICs.
The NGS program recently graduated its 140th fellow.
To our knowledge, there have been few capacity-building
efforts designed specifically for scientists in LMICs, and still
fewer that have attempted to assess their impact and suc-
cesses [7]. We sought to summarize the progress and les-
sons learned and to evaluate outcomes including research
output and influence on the participants’ subsequent career
trajectories.
Methods
Program origin and governance
The NGS program was established in 2011 as part of a
multi-faceted effort at Novartis to help build science cap-
acity in LMICs [14–16], and to provide opportunities for
industry scientists and clinicians to better understand
medical needs in diverse, traditionally underserved groups
[17]. The goal was to create an environment for mutual
learning [18] through scientist-to-scientist interactions
clustered around research activities tailored to the unique
needs of each fellow. Since 2014, the program has been
jointly coordinated with the University of Basel as a nat-
ural extension of the university’s long-standing work in
LMICs and as a leading center in Switzerland for
Africa-focused academic initiatives.
Fellows and scientific mentors
Each year from 2011 to 2017, an open call for applications
was disseminated through public channels. Applicants
were entered into a rigorous selection process comprising
a dossier review (curriculum vitae, description of research
interests, and essay-style letters of motivation and support)
and up to three rounds of interviews conducted by tele-
phone or in person. Interviews were led by academic re-
searchers, prospective scientific mentors, and trained
human resource professionals. Key selection criteria in-
cluded: academic credentials of the candidate (Master’s
equivalent and above); ability to match applicants’ research
interests and desired skills with an appropriate scientific
mentor and host laboratory; and candidates’ long-term
commitment to conduct biomedical or clinical research in
their home country. The University of Basel and Novartis
jointly approved the final cohort of candidates, which typ-
ically consisted of 20–25 fellows each year.
Scientific mentors at the University of Basel and
Novartis participated in a volunteer capacity. Generally,
this was because they wanted to engage in an
academic-style mentoring program, were interested in
the possibility of scientific collaborations with research
institutions in LMICs, or were motivated by the oppor-
tunity to personally contribute to the advancement of
science in LMICs. Mentors were selected based on their
specialties and their anticipated ability to dedicate suffi-
cient effort and be effective tutors. Many mentors chose
to participate over several years. Mentors were also of-
fered access to mentorship training programs and were
provided with operational support from a small core
team at University of Basel and Novartis responsible for
management of the program. The mentors also partici-
pated in periodic meetings for peer support and sharing
of mentorship best practices. Fellows and mentors
jointly developed a research plan according to the fel-
low’s interests and skills.
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Program structure
The 3-month core program comprised two main com-
ponents: a bespoke research project and a formally
structured science and leadership skills development
program. The research project occupied the fellow for
approximately 80% of the time spent on-site and was de-
signed to be sustainably implementable within infra-
structure at the fellow’s home institution. Research
interests of the selected candidates were identified from
their application dossiers and matched with prospective
mentors that had similar interests and relevant skillsets.
The scope of work for each fellow was then iteratively
refined through virtual (telephone and email) discussions
between candidates and mentors. Whenever feasible,
candidates’ home supervisors joined the pre-fellowship
discussions to contribute recommendations for technical
aspects that would benefit the fellow and the home insti-
tution. Once selected, mentors and mentees were typic-
ally in close contact leading up to commencement of the
on-site stay (e.g. to exchange background materials; to
attend to logistics of data and sample transfer; and to
guide the candidate to learn basic skills in preparation
for training that they would receive during the fellow-
ship). Topics in the scientific curriculum were allocated
to groups of fellows who planned and organized semi-
nars which facilitated bi-directional interactions with se-
nior experts. The leadership skills program comprised
workshops focused on written and oral scientific com-
munication, self-awareness, and appreciative inquiry
[19]. Workshops were highly interactive, immersive ex-
periences designed to enhance decision-making skills
and improve team leadership and management capabil-
ity. Over the 3-month period, fellows regularly convened
themselves to reflect on tactics to implement new ap-
proaches and methods at their home institutions.
In the final week of the program, fellows formally pre-
sented their research project in poster format at a public
scientific symposium. The graduation event typically in-
cluded oral presentations by a small number of graduating
fellows and by inspiring leaders in health and science from
LMICs. The University of Basel subsequently awarded a
University certificate and post-graduate credits using the
European Credit Transfer and Accumulation System, a
transferable standard for comparing study attainment and
performance in higher education across Europe [20].
Logistics and funding
The University of Basel organized and funded training
events that were hosted at their campus. Novartis funded
travel, accommodation, health insurance, immigration lo-
gistics, and provided a stipend. Laboratory-associated
costs were borne by the Novartis hosting laboratories.
Every effort was made to ensure that participation in the
program was cost-neutral to the fellows and their home
institutions. The program was compliant with Swiss law
and ethical, legal and financial guidelines of the University
of Basel and Novartis.
Networking and post-fellowship contact
Participants were co-located in student accommodation
which allowed for the development of a sense of com-
munity among fellows, provided an environment to con-
duct group project work in an informal setting, and
helped the development of a sustainable peer social and
professional network. After the fellowship, ongoing ex-
changes among fellows and their University of Basel and
Novartis mentors were encouraged.
Data sources and analysis methods
Demographic characteristics were extracted from fel-
lows’ application dossiers. Fellows’ research deliverables
(including research poster content and peer-reviewed
journal articles) were used to summarize and categorize
research activities.
Feedback was continually received over the evaluation
period through spontaneous verbal and electronic com-
munication. In addition, a global summit was convened
in 2014 and attended by approximately 60 fellows who
provided updates on their professional achievements at
that time.
In February 2017, an on-line follow-up survey
(Additional file 1) was distributed to all NGS fellows
who had participated in the program from 2011 to
2016. The 2017 cohort did not participate in this sur-
vey. The survey consisted of 18 multiple-choice and
open-ended questions that assessed fellows’ academic,
career and professional status, and evaluated their
perceptions of impact of the NGS program on their
professional trajectory and achievements.
Data and graphical analysis were performed using
RStudio (http://www.rstudio.com/), using library pack-
ages such as ggplot2 for generation of Figs. 1 and 2.
Results
There was an increasing trend in the number of applicants
to the NGS program over the duration of the program,
with a notable increase after the University of Basel joined
in 2014 as the co-host and accrediting academic partner
(Table 1). One-hundred and forty three scientists and cli-
nicians from LMICs took part during the 2011–2017
period reported in this paper. Demographic data and re-
search descriptions for all fellows selected are shown in
Table 2. Participants came from 73 institutions in 25
countries: Angola, Argentina, Brazil, Cameroon, China,
Costa Rica, Egypt, Ethiopia, Ghana, Kenya, Malaysia,
Mexico, Namibia, Nigeria, Peru, Philippines, Russia, South
Africa, Tanzania, Uganda, Ukraine, Venezuela, Vietnam,
Zambia and Zimbabwe (Fig. 1).
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The highest proportion of fellows was based in Africa
(62%). There was a predominance of doctoral or early
post-doctoral scientists (70%) and an even distribution
by gender (72 female and 71 male participants).
The majority (78%) of participants joined the program to
learn a new research methodology for implementation
back at their home institution. Others chose to develop
skills relating to clinical trials; access laboratory equipment,
infrastructure, and expertise; and/or use the fellowship to
facilitate analyses of their own samples or data. Several fel-
lows concentrated on skills relating to natural products,
reflecting their continuing relevance to research programs
in their local environments.
Fellows’ scientific focus was spread across basic research
laboratories, clinical research departments, and drug formu-
lation laboratories. Specific disease area interests were split
between communicable and non-communicable diseases.
The group comprised about 22% of clinician-scientists
Fig. 1 Geographic distribution of Next Generation Scientist fellows. NGS fellows were based at institutions in low- and middle-income countries
in Africa, Asia, Europe, and Latin America. Since 2011, 143 fellows from 25 countries have participated. Countries that contributed the highest
number of fellows were South Africa (n = 38) in the Africa region (62%) and Brazil (n = 15) in the Americas (22%)
Fig. 2 Total number of peer-reviewed publications before- and after- participation in the program. The column on the extreme left shows data
for all survey respondents as a boxplot. The horizontal bar inside the box shows the median; the box encloses the inter-quartile range i.e. 50% of
the data. The whiskers show the interval of values outside the box and values far outside are represented by points. The subsequent columns
show before-after publication output for each survey respondent from 6 cohorts, with the thick red line showing the median for the cohort.
Responses where before and after outputs were both zero have been excluded. The 2017 cohort did not participate in the follow-up survey
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(typically MD or equivalent with MSc, PhD or Post-doc)
most of whom were hosted in clinical research departments.
Follow-up data (Table 3 and Fig. 2) describing out-
comes in the post-fellowship period were available for
95% of fellows from the 2011–2016 cohorts (6 fellows
did not respond to the follow-up survey). Table 3 indi-
cates that there was significant professional development
as measured by progression to higher levels of trainings
or employment. Most participants remained in the pub-
lic sector and in academic settings in their countries of
origin. Several fellows (11%) reported that they had been
appointed to positions of leadership such as head of
their clinical department or research unit.
Figure 2 illustrates the total number of manuscripts
published in peer-reviewed journals before- and after
participation in the fellowship as reported in the survey.
These are shown for the full group of fellows and separ-
ately for each annual cohort of participants. An upward
slope of the median is noted for the earlier cohorts (e.g.
before 2014) and a flattening of the slope for the later
cohorts, which likely reflects the longer period that the
earlier cohorts had relative to the later cohorts to de-
velop their research careers and publish peer-reviewed
manuscripts.
Table 4 lists illustrative examples of program impact
on fellows’ careers and contributions to various scientific
disciplines. This table highlights more than 20 publica-
tions by NGS fellows and how their projects transferred
value to their home institutions. No comparative control
cohort data are available.
The follow-up survey revealed an enduring network after
completion of the 3-month fellowship. Nearly two-thirds of
participants (64%) reported ongoing regular contact with
other fellows and 35% reported sporadic contact. Only 3
fellows reported having no continuing contact with their
peers. Ongoing contact was also observed between fellows
and their mentors at University of Basel or Novartis; 86% of
fellows reported regular or sporadic contact. Active collab-
oration, as defined by ongoing project-related interactions,
was reported by 8% of fellows for peer-to-peer partnerships
and by 12% of fellows for fellow-to-mentor partnerships.
In open-ended comments on the follow-up survey,
NGS fellows reported concrete scientific benefits such as
access to equipment and data; expediting completion of
post-graduate qualification; and “soft” benefits including
networking, reputation, and broadened perspectives on
work ethic and culture. Fellows also reported improve-
ments in research productivity via publications, confer-
ence presentations, success with funding applications
and involvement in clinical trials. As a complement to
individual scientific research development, the respondents
also provided examples where they themselves transferred
skills to colleagues at home. Table 5 provides a summary
Table 1 Number of applicants, number selected and number of
survey respondents per cohort year
Year Applications Receiveda Fellows Selected (%) Respondents to
2017 Survey (%)
2011 27 15 (56) 13 (87)
2012 37 20 (54) 17 (85)
2013 108 23 (21) 23 (100)
2014 308 22 (7) 22 (100)
2015 224 20 (9) 20 (100)
2016 263 20 (8) 19 (95)
2017 219 23 (11) n/a
aAfter removing duplicates and only retaining applications from low- and
middle-income countries
Table 2 Demographics of participants at the start of the 3-month
fellowship (n = 143)
General
Gender (female) 72 (50%)
Median age (25th–75th percentile) 29 (27–33)
Region (Country)
Americas (Argentina, Brazil, Costa Rica, Mexico,
Peru, Venezuela)
32 (22%)
Africa & Eastern Mediterranean (Angola, Cameroon,
Egypt, Ethiopia, Ghana, Kenya, Namibia, Nigeria,
South Africa, Tanzania, Uganda, Zambia, Zimbabwe)
88 (62%)
Western Pacific (China, Malaysia, Philippines, Vietnam) 10 (7%)
Europe (Russian Federation, Ukraine) 13 (9%)
Training level
Master’s 43 (30%)
PhD 89 (62%)
Post-doctoral 11 (8%)
Professional statusa
Student 88 (62%)
Public sector (including academia) 47 (33%)
Private sector (including pharma) 8 (6%)
Medical doctor 31 (22%)
Fellowship research focusa
Development of a specific methodology (e.g.,
laboratory protocol or standard operating procedure)
111 (78%)
Training on planning or conduct of clinical trials 34 (24%)
Access to laboratory equipment, infrastructure
and expertise
29 (20%)
Analysis of samples or data from the fellow’s
own institution
14 (10%)
Fellowship scientific discipline
Biological targets and pathways 32 (22%)
Chemistry, formulation, or analytical sciences 42 (29%)
Clinical research 55 (39%)
Genetics and genomics 14 (10%)
aCategories are not mutually exclusive
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of the benefits of the program as reported by NGS fellows
and their mentors.
Discussion
A 7-year structured, immersive mentorship program
contributed to professional development for a carefully
selected group of 143 scientists and clinicians from 25
LMICs. A unique feature of the program was the bring-
ing together of cohorts of researchers at the launch stage
of their scientific careers. This appears to have facilitated
a sustained network of scientists in LMICs despite the
relatively short 3-month duration of the on-site compo-
nent. The governance of the NGS program was also
novel, with voluntary shared responsibility by a range of
academic, public, and private partners. Understanding
key enablers of the program, and its limitations up until
now, is fundamental to improving the program in the fu-
ture and may inform the design and implementation of
similar capacity-building efforts in LMICs.
A widely acknowledged success that was highlighted
by fellows and mentors was the opportunity for mutual
learning in topic areas that would not easily be attained
through other mechanisms. By design, fellows benefited
from specific scientific and professional development
training. In many cases, mentors similarly benefited
from the knowledge exchange (e.g., relating to natural
products; pharmacogenetics in diverse populations; and
first-hand accounts of health priorities). In nearly all
cases, mentors stated that the lessons they learned about
patients, diseases, and health systems in LMICs broad-
ened their perspectives about science and medicine glo-
bally in ways that influenced their own professional and
personal activities. This gives credence to the Nigel
Crisp assertion that “rich countries can learn a great deal
about health and health services from poorer ones and
that combining the learnings from rich and poor coun-
tries can give us new insights into how to improve
health” [18]. We suspect that the reciprocated respect
that developed between fellows and mentors because of
shared learning experiences played an important role in
paving the way for continued joint collaborations in the
post-fellowship period.
Another program enabler was the flexibility associated
with fellows’ research curricula. Fellows were not
pigeon-holed towards pre-determined activities—rather, re-
search programs were individualized according to the needs
of each fellow, agreement between fellows and mentors,
and relevance to priorities at fellows’ home institutions and
countries. The hosting laboratories at Novartis needed to
be able to support the science that the fellow would con-
duct, but the fellow’s research program did not need to dir-
ectly advance the research agenda of the hosting laboratory.
Providing support for fellows’ research interests was not al-
ways entirely straightforward. For example, some projects
involved analysis of plant or biological samples from fel-
lows’ home institutions, which required considerable effort
by both the home and host institutions to ensure compli-
ance with the ethical-legal regulations associated with
cross-border transfer of materials. The benefit, however,
was scientific progress and attainment of valuable experi-
ence on both sides for implementing globally-focused sci-
entific research. For all projects, research success was a
result of thorough planning before the fellowship and
on-going interactions afterwards. It was felt that tailoring
activities to the needs of fellows was a significant factor in
the impressive scientific productivity that resulted (for ex-
ample see the peer-reviewed publications cited in Table 4)
despite the short 3-month duration of the on-site phase.
The high retention of fellows in their home countries
(> 75%) and employment in the public or academic sec-
tor is noteworthy - only 4 scientists reported working
for a pharmaceutical company after completion of their
studies in contrast to over 60% being employed in the
public or academic sector (Table 3). Although we ac-
knowledge that private sector employment for highly
trained researchers is scarce in LMICs, we were
Table 3 Professional progression of participants in the post-fellowship period (n = 120 at baseline; n = 114 at follow-up)
Baseline (2011–2016)a Follow-up (2017)
Number of NGS fellows located outside country of citizenshipa 15 (13%)b 26 (23%)c
Highest training level
Master’s student 35 (29%) 0 (0%)
PhD student 76 (63%) 61 (54%)
Post-doctoral 9 (8%) 53 (46%)
Employment status
Student 71 (59%) 27 (24%)
Public sector (including academia) 43 (36%) 73 (64%)
Private sector (including pharma) 6 (5%) 14 (12%)
aThe 2017 cohort did not participate in the follow-up survey
bAll were pursuing post-graduate study in South Africa
cIn post-doctoral training positions: 10 in the USA, 7 in Europe and 3 in South Africa. In full-time employment: 2 in USA and 1 in Europe and 4 in South Africa
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nevertheless encouraged by this result, given valid
concerns that inviting high caliber scientists into
well-resourced research environments might further
contribute to the “brain drain” from these countries [4–
6]. Factors related to this success likely include: an
unambiguously stated goal of the program for local
Table 4 Examples of NGS program outputs and outcomes
Fellowship research focus Outputs and outcomes
Development of a methodology (e.g., laboratory
protocol or standard operating procedure)
A medicinal chemistry doctoral student from Kenya improved chemical inhibition
phenotyping assays used to predict drug-drug interaction potential of new molecular
entities [23]; the method was subsequently transferred to the H3D Drug Discovery and
Development Centre at the University of Cape Town where he was completing his PhD
studies.
A pharmacologist from Tanzania developed a rapid and reliable reversed phase high
performance liquid chromatography method for simultaneous determination of selected
anti-retroviral agents and lumefantrine in human plasma [24]; the method was successfully
transferred to her home laboratory, facilitated completion of her PhD, and is being used by
other post-graduate students at that institution researching HIV-malaria co-infection.
A molecular biologist from Argentina developed a high-throughput screening assay for a
drug target for Brucella abortus, the causative organism for brucellosis, a zoonotic infection
that affects livestock and humans. Ten compounds with promising potency were identified
after screening 44,000 compounds. This work facilitated completion of her doctoral
thesis [25, 26] and formed the basis of a successful grant application at her research
institute in Buenos Aires.
A pharmacologist from Nigeria evaluated the herb-drug interaction potential of natural
products in common use in his country [27, 28]. This facilitated the completion of his
doctoral studies and transfer of the in vitro metabolism study methods to his institution in
South Africa, and helped to enable his subsequent post-doctoral and faculty appointment.
A cellular and molecular biologist from Brazil conducted laboratory studies to develop
mechanistic understanding of cell surface immune responses of helper T cells. This facilitated
continuation of his doctoral studies on Chagas disease [29]. The methodologies were used
by his home laboratory to conduct in vitro assays to examine the role of the different T-cell
subsets and cytokines in disease progression.
Training on planning or conduct of clinical trials A medical doctor from South Africa obtained practical skills in operational planning and
execution of first-in-human (FIH) studies [14] that were subsequently applied to a FIH study
of a malaria drug candidate discovered at H3D in partnership with Medicines for Malaria
Venture [30]. She continues with an active clinical pharmacology research agenda including
studies to understand pharmacogenetics and clinical response [31].
A medical oncologist from Brazil worked with an early clinical development team to learn
procedures relating to trial protocol amendments. This facilitated direct interaction with in-
house experts for input into her doctoral studies [32–35]. Upon return to her clinic in Brazil,
she continued as clinical investigator on multiple oncology translational medicine clinical
studies.
A medical doctor from Ethiopia compared mechanistic explanations of drug induced liver
injury across multiple publicly available clinical candidates [36]. He also acquired clinical trial
skills and networks to establish a clinical pharmacology unit [14] after his return to Ethiopia,
and has an active senior role in multiple aspects of clinical research.
Access to laboratory equipment, infrastructure
and expertise
A geneticist from South Africa documented genetic diversity in Black South Africans from
Soweto, learned bioinformatics techniques, and constructed a large database of African
genetic diversity for further analyses and training purposes [37].
A geneticist from South Africa identified a novel mutation in the CHST6 gene as a cause of
macular corneal dystrophy in a Black South African family, which was used for genetic
counselling of the family [38].
A drug formulation scientist from Kenya assessed alternate liposomal parenteral formulations
to solubilize poorly soluble drug substances while working with the nano-technology unit.
He applied these technologies to potential anti-malarial drug formulations [39, 40] as part of
his doctoral studies. He currently collaborates with South African scientists and their team
has been successful in grant applications relating to malaria research.
Analysis of samples or data from the fellow’s own
institution
A medicinal chemist from Kenya evaluated the metabolism and pharmacokinetics for a series
of new deoxyamodiaquine-based compounds. This work was directly applied to the drug
discovery program at H3D [41].
A pharmacognocist/phytochemist from Ghana assessed natural products to demonstrate
anti-plasmodial and medicinal potential [42, 43]. These initial studies played a key role in the
expansion of the natural products research laboratory at his home institution.
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capacity development rather than staff recruitment; a
rigorous selection process capable of identifying candi-
dates with a desire to contribute to their local healthcare
research; and the short 3-month on-site stay. In some
cases, this was assisted by strong links with home super-
visors who provided an enabling home base to return to
and continue on a rejuvenated career trajectory.
The NGS program’s multi-sectoral academic-public-private
partnership model worked well. Involvement of the
University of Basel as a coordinating entity was instru-
mental in providing academic credibility, and the col-
laborative framework that developed with science as an
organizing principle helped the industry partner to be
viewed as an equal contributor rather than simply a
funding source. Within LMICs, the program often
served as a complement to locally funded government
or non-governmental capacity-building initiatives and
in some instances stimulated the establishment of new
partnership programs.
Much has been written to acknowledge the secondary
effects of strengthening research capacity on health in
under-resourced environments. These viewpoint and
perspectives papers typically highlight existing programs
and advocate for new collaborative efforts involving local
and international governments, private sector groups
and large funding bodies [2, 3]. The program described
here has similarities in its genesis and goals with the
Career Development Fellowship (CDF), jointly adminis-
tered by the World Health Organization’s Special
Programme for Research and Training in Tropical Dis-
eases (WHO/TDR) and the European & Developing
Countries Clinical Trials Partnership (EDCTP) [7]. The
CDF was founded as a partnership involving a pharma-
ceutical company, GlaxoSmithKline Biologicals, and has
been independently evaluated as being relevant, efficient
and effective with potential for impact and sustainability.
However despite expansion to include multiple partners,
the number of participants reported in the evaluation
remain modest [7], which we believe underscores the
need for more programs such as these.
Future priorities for the NGS program will be to in-
crease involvement of the home academic supervisors.
Our experience has been that home supervisor involve-
ment leads to more successful project outcomes,
whereas a lack of involvement could make the reintegra-
tion to the home laboratories more difficult. Fellows
have highlighted that whilst techniques are relatively
easy to transfer back, research culture traits can be more
difficult due to a confounding interplay of culture and
infra-structure deficits between research sites located in
high-income countries and the academic centers in
LMIC settings. Closer engagement with the home men-
tors and institutions might represent one component of
a solution. Ideally this would be coupled with enriched
and expanded post-fellowship activities. There has been
substantial interest from NGS fellows in formalizing
post-fellowship interactions, in part due to recognition
of the benefits that could be realized by capitalizing on
their large, growing network of emerging scientific
leaders in LMICs. Preferably, this will be accomplished
by putting primary governance of the activities with the
fellows themselves. As with many capacity-building ef-
forts, we are currently faced with the challenge of identi-
fying methods for scaling up the program while
maintaining the individualized approach that is thought
to be crucial to the program’s success. We have initiated
exploratory high-level discussions with several major re-
search funding organizations and are hopeful that the
program can be grown in future program cycles.
The above benefits described notwithstanding, we ac-
knowledge that there are limitations to capacity-building
via the approach described, and there were also limita-
tions to our ability to evaluate the program. As with all
survey-type methodologies there is the possibility of
reporting bias, though we took the exceedingly high re-
sponse rate (ranging 87–100% across the 7 cohorts of
Table 5 Program benefits reported by NGS fellows, home institution supervisors and host institution mentors
Fellows and supervisors Mentors
Access to data, biomedical technologies, and industry scientific expertise Insights into local health care system and infrastructure in low
and middle income countries (LMICs)
Enhanced skills to formulate relevant and impactful research questions Insights into differences in disease manifestation and patient
needs between LMICs and high-income countries (HICs)
Opportunities for networking and collaboration (e.g., with NGS fellows,
industry colleagues, academic collaborators through networks created
during the fellowship)
Development of collaborative relationships with local academic
centers with similar or complementary research interests
Expedited completion of post-graduate qualification Contribution to a social responsibility-driven mission
Improved understanding of career opportunities in industry and academia
Development of local scientists and heightened global awareness of
research environment
Increased professional confidence, success in securing employment and
leadership positions
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participants) as a sign that reporting bias in this evalu-
ation was likely to be minimal. To mitigate potential bias
by the program funders (Novartis and the University of
Basel) in the evaluation of the program, we assembled a
multi-sectoral public-academic-private team to conduct
the study reported here. This team included some super-
visors of NGS fellows from their home institutions and
were thus in a position to contextualise the overall sur-
vey data against their own personal impressions of the
impact of the program on their students. The core com-
ponent of the NGS program is a 3-month intensive
mentored research experience, and there are natural
confines to the extent of professional development that
can be achieved in this time-limited period. While for
many participants the core program set into motion
long-term collaborative activities (which was encour-
aged), these activities were not supported with dedicated
resources. Another potential inherent weakness with the
program design was mentoring of fellows outside of
their home institution. This required added financial re-
sources and logistical considerations, and temporarily re-
moved scientists from the precise environments where
capacity-building is needed. However, the rationale was
to enable sufficient exposure to new resources (e.g.,
other scientists, laboratories, tools, and technologies)
that would enrich their professional development; in
addition, this approach served to facilitate peer-to-peer
networks that would likely not have been established to
the same degree without bringing fellows together
face-to-face. Quantifying and valuing the multiple hard
and soft dimensions of long-term impact of capacity de-
velopment programs remain challenging. Logistical im-
practicalities preclude the conduct of a controlled study
– we propose the development of methods to quantify
the social impact of capacity development programs in
monetary terms, similar to the valuation of an environ-
mental footprint [21, 22]. The current evaluation may
have been confounded because the NGS program appli-
cation process favored selection of high-performing
candidates, and because fellows were unable to keep re-
sponses in the online follow-up survey confidential from
the program organizers who administered the survey.
Nevertheless, we believe that the very high response rate
to the follow-up survey, which was conducted up to
6 years after participation, coupled with meaningful
self-reported outputs, is an indicator that many fellows
felt that the NGS program had tangible benefits to their
professional development.
Conclusions
This 7-year structured, immersive mentorship program with
143 scientists and clinicians from 25 LMICs provides an
example for how multi-sectoral partners can contribute to
scientific and professional development of researchers in
LMICs. Our experience substantiates the view that
capacity-building efforts in LMICs should be tailored to the
specific needs of beneficiaries to be maximally effective. Les-
sons learned may be applied to the design and conduct of
other programs to strengthen science ecosystems in LMICs.
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